Kunal Jobanputra, Medical Oncologist at the Saifee Hospital, shared on X:
“Our work from Tata Memorial Hospital published in JCO Global Oncology.
Largest single-centre Indian study of intermediate-/poor-risk NSGCT.
- n = 400
- Median follow-up: 60.2 mo.
5-year outcomes (Our cohort vs IGCCCG 2021)
Intermediate-risk
- RFS: 77.0% vs 78%
- OS: 84.6% vs 89%
Poor-risk
- RFS: 45.6% vs 54%
- OS: 52.6% vs 67%
Poor-risk had inferior outcomes compared to IGCCCG.
Six-factor prognostic model:
- Age ≥35 years
- Mediastinal primary
- Lung metastasis
- Liver metastasis
- Brain metastasis
- AFP >10,000 (OS) / LDH >10× ULN (RFS)
‘Poorest-risk’ subgroup (≥3 adverse factors). 5-year OS: 27.1% – UNMET NEED.
Adds granularity beyond current IGCCCG risk groups and provides framework for future treatment-intensification in selected cohort of patients.
Grateful to Amit Joshi for conceptualizing this study and entire GU DMG team at Tata Memorial Hospital.”
Title: Prognostic Reclassification and Survival Outcomes in Intermediate-Risk and Poor-Risk Nonseminomatous Germ Cell Tumors: Single-Institution Experience From Western India
Authors: Kunal Jobanputra, Aditya Dhanawat, Gagan Prakash, Amandeep Arora, Sayak Dey, Akash Pawar, Bhagyashri Jadhav, Nandini Menon, Minit Shah, Mahendra Pal, Ganesh Bakshi, Vedang Murthy, Priyamvada Maitre, Palak Popat, Nilesh Sable, Aparna Ringe-Katdare, Archi Agrawal, Santosh Menon, Vanita Noronha, Kumar Prabhash, Amit Joshi
Read the full article.
